Karl Mulligan, PhD, has over 20 years experience in cancer research and the commercial life sciences sector. Since October 2014 he has held the position of Chief Operating Officer and Co-Founder of CV6 Therapeutics (NI) Ltd, an early stage drug development company.

In addition he is an Entrepreneur in residence at the Northern Ireland Science Park, specialising in product development and commercialisation strategies for early stage life science products and start up companies. Previously he was the senior manager of a successful diagnostics start up company that was acquired by the Almac Group Ltd. As Global Vice President of Almac Diagnostics he established and managed R&D, Operational and Clinical testing facilities in both the UK and USA.

The multi-disciplinary teams he managed were responsible for generating novel technologies/diagnostics, and providing services to Biotech and Pharmaceutical companies in support of their drug and companion diagnostic development programmes. He obtained his BSc (Hons) from the University of Liverpool and his PhD in molecular oncology from Queen’s University, Belfast.